Resistance to ceftazidime-avibactam in a KPC-2-producing Klebsiella pneumoniae caused by the extended-spectrum beta-lactamase VEB-25.

Findlay, J ; Poirel, L ; et al.

In: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, Jg. 42 (2023-05-01), Heft 5, S. 639-644

Online academicJournal

Wie komme ich dran?

Zugriff:

Zum Volltext

Carbapenem-resistant Enterobacterales, including KPC-producing Klebsiella pneumoniae, represent a major threat to public health due to their rapid spread. The beta-lactam/beta-lactamase inhibitor (BL/BLI) combination ceftazidime-avibactam (CAZ-AVI) has recently been introduced and shown to exhibit excellent activity toward multidrug-resistant KPC-producing Enterobacterales strains. However, CAZ-AVI-resistant K. pneumoniae isolates are being increasingly reported, mostly corresponding to producers of KPC variants that confer resistance to CAZ-AVI but at a cost of carbapenem resistance. We have characterized here, both phenotypically and genotypically, a clinical CAZ-AVI- and carbapenem-resistant KPC-2 K. pneumoniae isolate co-producing the inhibitor-resistant extended-spectrum beta-lactamase VEB-25.

Titel:	Resistance to ceftazidime-avibactam in a KPC-2-producing Klebsiella pneumoniae caused by the extended-spectrum beta-lactamase VEB-25.
Autor/in / Beteiligte Person:	Findlay, J ; Poirel, L ; Bouvier, M ; Gaia, V ; Nordmann, P
Link:	Zum Volltext
Zeitschrift:	European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, Jg. 42 (2023-05-01), Heft 5, S. 639-644
Veröffentlichung:	Berlin : Springer ; <i>Original Publication</i>: [Wiesbaden, Federal Republic of Germany] : Vieweg, [c1988-, 2023
Medientyp:	academicJournal
ISSN:	1435-4373 (electronic)
DOI:	10.1007/s10096-023-04582-0
Schlagwort:	Humans Anti-Bacterial Agents pharmacology Anti-Bacterial Agents therapeutic use Klebsiella pneumoniae beta-Lactamases genetics Ceftazidime pharmacology Drug Combinations Carbapenems pharmacology beta-Lactamase Inhibitors pharmacology beta-Lactamase Inhibitors therapeutic use Microbial Sensitivity Tests Bacterial Proteins genetics Carbapenem-Resistant Enterobacteriaceae Klebsiella Infections drug therapy Klebsiella Infections microbiology
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Eur J Clin Microbiol Infect Dis] 2023 May; Vol. 42 (5), pp. 639-644. <i>Date of Electronic Publication: </i>2023 Mar 06. MeSH Terms: Carbapenem-Resistant Enterobacteriaceae* ; Klebsiella Infections* / drug therapy ; Klebsiella Infections* / microbiology ; Humans ; Anti-Bacterial Agents / pharmacology ; Anti-Bacterial Agents / therapeutic use ; Klebsiella pneumoniae ; beta-Lactamases / genetics ; Ceftazidime / pharmacology ; Drug Combinations ; Carbapenems / pharmacology ; beta-Lactamase Inhibitors / pharmacology ; beta-Lactamase Inhibitors / therapeutic use ; Microbial Sensitivity Tests ; Bacterial Proteins / genetics References: Euro Surveill. 2020 Jan;25(3):. (PMID: 31992391) ; Antimicrob Agents Chemother. 2019 Sep 16;:. (PMID: 31527032) ; Antimicrob Agents Chemother. 2014 Oct;58(10):5696-703. (PMID: 25022583) ; Clin Infect Dis. 2016 Jul 15;63(2):234-41. (PMID: 27098166) ; J Antimicrob Chemother. 2016 Oct;71(10):2848-55. (PMID: 27402011) ; Clin Microbiol Infect. 2008 Jan;14 Suppl 1:42-52. (PMID: 18154527) ; J Antimicrob Chemother. 2012 Nov;67(11):2640-4. (PMID: 22782487) ; Int J Antimicrob Agents. 2012 Jan;39(1):86-9. (PMID: 22041508) ; PLoS Comput Biol. 2017 Jun 8;13(6):e1005595. (PMID: 28594827) ; Antimicrob Agents Chemother. 2016 Apr 22;60(5):3183-6. (PMID: 26926646) ; Eur J Clin Microbiol Infect Dis. 2022 Nov;41(11):1355-1360. (PMID: 36103096) ; Antimicrob Agents Chemother. 2014 Jul;58(7):3895-903. (PMID: 24777092) ; Antimicrob Agents Chemother. 2015 Jul;59(7):3710-7. (PMID: 25666153) ; JAC Antimicrob Resist. 2021 Jul 16;3(3):dlab092. (PMID: 34286272) ; Bioinformatics. 2014 Jul 15;30(14):2068-9. (PMID: 24642063) ; Antimicrob Agents Chemother. 2017 Dec 21;62(1):. (PMID: 29061741) ; Antimicrob Agents Chemother. 1999 Mar;43(3):573-81. (PMID: 10049269) ; Genome Med. 2022 Aug 23;14(1):97. (PMID: 35999578) ; Euro Surveill. 2020 Jan;25(2):. (PMID: 31964461) ; Genome Res. 2017 May;27(5):722-736. (PMID: 28298431) ; J Glob Antimicrob Resist. 2021 Jun;25:268-281. (PMID: 33895414) ; Microb Genom. 2018 Aug;4(8):. (PMID: 30052170) ; J Antimicrob Chemother. 2022 Nov 28;77(12):3487-3495. (PMID: 36245258) ; mSphere. 2021 Jun 30;6(3):e0042421. (PMID: 34077263) Contributed Indexing: Keywords: Ceftazidime-avibactam; KPC; Klebsiella pneumoniae; VEB Substance Nomenclature: 0 (avibactam, ceftazidime drug combination) ; 0 (Anti-Bacterial Agents) ; EC 3.5.2.6 (beta-Lactamases) ; 9M416Z9QNR (Ceftazidime) ; 0 (Drug Combinations) ; 0 (Carbapenems) ; 0 (beta-Lactamase Inhibitors) ; 0 (Bacterial Proteins) Entry Date(s): Date Created: 20230306 Date Completed: 20230418 Latest Revision: 20230418 Update Code: 20231215 PubMed Central ID: PMC10105652

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.